Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-06-06
1999-03-02
Reamer, James H.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514213, 514339, 514250, 514866, 514909, A61K 3144
Patent
active
058771832
ABSTRACT:
Provided are methods for the regulation and modification of lipid and glucose metabolism by administering to a subject a dopamine D1 agonist, optionally in combination with a dopamine D2 agonist, an alpha-1 adrenergic antagonist, an alpha-2 adrenergic agonist, or a serotonergic inhibitor, or optionally in combination with a dopamine D2 agonist coadministered with at least one of alpha-1 adrenergic antagonist, an alpha-2 adrenergic agonist, or a serotonergic inhibitor, and further administering the subject a serotonin 5HT.sub.1b agonist.
REFERENCES:
patent: 4783469 (1988-11-01), Meier et al.
patent: 4971969 (1990-11-01), Carlier et al.
patent: 5344832 (1994-09-01), Cincotta et al.
patent: 5468755 (1995-11-01), Cincotta et al.
patent: 5585347 (1996-12-01), Meier et al.
International Preliminary Examination Report dated Apr. 1, 1998 received in the corresponding PCT application.
Ergo Research Corporation
Reamer James H.
LandOfFree
Treatment of lipid and glucose metabolism disorders with dopamin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of lipid and glucose metabolism disorders with dopamin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of lipid and glucose metabolism disorders with dopamin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-423156